Valeant Pharmaceuticals (VRX.TO) Buy, Sell or…

Valeant Pharmaceuticals (VRX.TO)

0.00

-0.00 (0.00%)

39 watching

DON'T BUY

Has had trouble being positive on this company for many years. Views it as a 3rd rate drug company. They don't develop their own products. Management has always been suspect.

Wealthica Track your Stocks in your Watch List

TOP PICK

Good opportunity for about one to one and a half years. Have talked about acquisitions and if they do a significant one it could result in reducing or eliminating dividends. Likes their Huntington product and they are also testing a Viagra-like product.

TOP PICK

Believes the dividend of 13.86% is sustainable. Generates a significant amount of free cash flow. Also have over $300 million in cash and no debt. Changing their strategy by looking to develop drugs for the central nervous system. That area has good growth. Many good acquisition last year.

PAST TOP PICK

(A Top Pick March 26/08. Up 29.8%.)

DON'T BUY

Pretty good cash flow and have a lot of cash and they can afford to pay the 13.3% yield. The question is, whether they use the cash to acquire other product lines. Does like the Bio Pharma space and the ethical pharmaceutical companies but he would prefer one with more growth.

TOP PICK

Has a fabulous dividend, which is relatively safe unless it makes a huge acquisition. Very strong lines of business. Good management.

BUY

Healthcare in general is screening very well. Nice yield up 13%. A defensive name. Also likes Neostem (NBS-A) and Cardiome Pharma (COM-T) in this group.

BUY

New CEO. Company is doing a turnaround. Cutting expenses. Still closing the Puerto Rican facilities. Acquired a new drug that has been FDA approved and sales have been pretty good. Another drug is in phase 3 testing. Would shave the dividend if needed for a new acquisition.

Wealthica Track your Stocks in your Watch List

HOLD

Attractive right now because it pays a good dividend and has a good cash balance. This is a transition stock because their main cash cow, Wellbutrin, is becoming generic. Competition is coming in. Thinks cash flow will be reduced rapidly in the next 12 to 18 months. Dividend is not sustainable.

DON'T BUY

Dividends a little on the high side. Company has stated that if they make an acquisition, dividend will be cut.

BUY

Has a terrific yield. Stock on a price to book basis is not that expensive. Could easily see another 25%-30% conservatively.

HOLD

Wait for this to come back a little before Buying. Monthly indices for healthcare sector rank very well. Broke out of what looks like an inverted head and shoulders pattern. If it can get through the resistance level set last May, you could be looking at the $14 level.

BUY

Has gone through some difficulties in the last little while because of potential change of control. This is now behind them and the company is in good shape to move up. Have a good stable of products. 16.8% yield should be safe but if it gets cut, it wouldn't bother him.

DON'T BUY

Negative growth rate would be of some concern to him. Isn't expensive but the question is if the business will continue to deteriorate. We prefer others.

BUY

Chequered history but a lot of it is in the past. Attempting to reinvent itself. New management. New strategy of buying new drugs. (E.G. Central Nervous System is a new space.) Dividend could be at risk.

Showing 256 to 270 of 714 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Valeant Pharmaceuticals (VRX.TO)